Bevacizumab treatment and HOXB9 expression. Subcutaneous xenografts of HT 29-T cells in Balb/c nu/nu mice were treated with bevacizumab (n = 8, each). Tumor growth under bevacizumab treatment were evaluated in tumor burden (a), tumor weight (b), tumor specimen (c), and tumor inhibition rate (d). (e) Tumor inhibition rate was calculated in HT 29-T on day 13. Error bars are SDs. ☆p < 0.05 and † p < 0.005 by U-test.